Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer

Qianyi Lu, Wen Xia, Kaping Lee, Jingmin Zhang, Huimin Yuan, Zhongyu Yuan, Yanxia Shi, Shusen Wang, Fei Xu, Qianyi Lu, Wen Xia, Kaping Lee, Jingmin Zhang, Huimin Yuan, Zhongyu Yuan, Yanxia Shi, Shusen Wang, Fei Xu

Abstract

Lessons learned: Studies targeting the androgen receptor (AR) signaling pathway in aromatase inhibitor (AI)-resistant breast cancer are limited. Bicalutamide, one of the commonly used AR inhibitors in prostate cancer, in combination with AI, did not show synergistic activity in patients with estrogen receptor-positive and AI-resistant disease in this phase II, single-arm study. The clinical benefit rate and objective response rate at 6 months were 16.7% and 0%, respectively, and the study was terminated after the first stage.

Background: Endocrine resistance is a major problem in clinical practice. Studies have shown that androgen receptor (AR) signaling activation may be one of the mechanisms, and targeting AR showed some promising results in AR-positive triple-negative breast cancer. The aim of this study was to assess the efficacy and safety of bicalutamide plus another aromatase inhibitor in patients with nonsteroidal aromatase inhibitor (AI) or steroidal AI resistance and estrogen receptor (ER)-positive and AR-positive advanced breast cancer.

Methods: A Simon's two-stage, phase II, single-arm study was conducted. We assumed the clinical benefit rate (CBR) of 40% would be significant in clinical practice. In this case, if ≥4 patients of the 19 patients in the first stage benefited from treatment, the CBR would achieve the assumed endpoint. If fewer than four patients benefited from treatment in the first stage, the trial would be terminated. All patients received bicalutamide 50 mg per day orally plus another aromatase inhibitor. The primary outcome was CBR; secondary outcomes included objective response rate (ORR), progression-free survival (PFS), and tolerability.

Results: A total of 19 patients enrolled in the first stage, and 18 patients met all criteria for analysis. The trial terminated according to protocol after the first stage. After a median follow-up of 14 months, the CBR at 6 months was 16.7% (3/18); no patients with partial or complete response were observed. The median PFS was 2.7 months. Bicalutamide in combination with AI was well tolerated.

Conclusion: Bicalutamide in combination with another AI did not show synergistic activity in patients with ER-positive breast cancer and AI resistance. Results suggest that no more large-sample clinical trials should be conducted in this population for overcoming endocrine resistance.

Trial registration: ClinicalTrials.gov NCT02910050.

© AlphaMed Press; the data published online to support this summary are the property of the authors.

Figures

Figure 1
Figure 1
CONSORT flow diagram. Abbreviations: CBR, clinical benefit rate; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival.
Figure 2
Figure 2
Progression‐free survival of all patients.

References

    1. Miller WR, Larionov AA. Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res 2012;14:201.
    1. Park S, Koo J, Park HS et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010;21:488–492.
    1. Grogg A, Trippel M, Pfaltz K et al. Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer 2015;15:872.
    1. Witzel I, Graeser M, Karn T et al. Androgen receptor expression is a predictive marker in chemotherapy‐treated patients with endocrine receptor‐positive primary breast cancers. J Cancer Res Clin Oncol 2013;139:809–816.
    1. Qu Q, Mao Y, Fei XC et al. The impact of androgen receptor expression on breast cancer survival: A retrospective study and meta‐analysis. PLoS One 2013;8:e82650.
    1. Ciupek A, Rechoum Y, Gu G et al. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα‐positive breast cancer. Breast Cancer Res Treat 2015;154:225–237.
    1. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N‐terminal domain by interleukin‐6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277:7076–7085.
    1. Tarulli GA, Butler LM, Tilley WD et al. Bringing androgens up a NOTCH in breast cancer. Endocr Relat Cancer 2014;21:T183–T202.
    1. Fujii R, Hanamura T, Suzuki T et al. Increased androgen receptor activity and cell proliferation in aromatase inhibitor‐resistant breast carcinoma. J Steroid Biochem Mol Biol 2014;144:513–522.
    1. Anestis A, Sarantis P, Theocharis S et al. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor‐positive triple‐negative breast cancer. J Cancer Res Clin Oncol 2019;145:1221–1233.
    1. Giovannelli P, Di Donato M, Auricchio F et al. Androgens induce invasiveness of triple negative breast cancer cells through AR/Src/PI3‐K complex assembly. Sci Rep 2019;9:4490.
    1. Kono M, Fujii T, Lim B et al. Androgen receptor function and androgen receptor‐targeted therapies in breast cancer: A review. JAMA Oncol 2017;3:1266–1273.
    1. Masiello D, Cheng S, Bubley GJ et al. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002;277:26321–26326.
    1. Gucalp A, Tolaney S, Isakoff SJ et al.; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor‐positive, estrogen receptor‐negative metastatic breast cancer. Clin Cancer Res 2013;19:5505–5512.
    1. Schwartzberg LS, Yardley DA, Elias AD et al. A phase I/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer. Clin Cancer Res 2017;23:4046–4054.
    1. Bonnefoi H, Grellety T, Tredan O et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple‐negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12‐1). Ann Oncol 2016;27:812–818.
    1. O'Shaughnessy J, Campone M, Brain E et al. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor‐positive metastatic breast cancer. Ann Oncol 2016;27:106–113.
    1. Yardley DA, Noguchi S, Pritchard KI et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO‐2 final progression‐free survival analysis. Adv Ther 2013;30:870–884.
    1. Lin Fde M, Pincerato KM, Bacchi CE et al. Coordinated expression of oestrogen and androgen receptors in HER2‐positive breast carcinomas: Impact on proliferative activity. J Clin Pathol 2012;65:64–68.
    1. Thike AA, Yong‐Zheng Chong L, Cheok PY et al. Loss of androgen receptor expression predicts early recurrence in triple‐negative and basal‐like breast cancer. Mod Pathol 2014;27:352–360.
    1. Vera‐Badillo FE, Templeton AJ, de Gouveia P et al. Androgen receptor expression and outcomes in early breast cancer: A systematic review and meta‐analysis. J Natl Cancer Inst 2014;106:djt319.
    1. Kensler KH, Regan MM, Heng YJ et al. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor‐positive breast cancer: Results from the Breast International Group Trial 1‐98. Breast Cancer Res 2019;21:30.
    1. Pietri E, Massa I, Bravaccini S et al. Phase II study of dehydroepiandrosterone in androgen receptor‐positive metastatic breast cancer. The Oncologist 2019;24:743‐e205.
    1. Krop I, Abramson V, Colleoni M et al. Results from a randomized placebo‐controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor‐positive breast cancer. Cancer Res 2018;78(suppl 4):GS4‐07A.
    1. Ma CX, Reinert T, Chmielewska I et al. Mechanisms of aromatase inhibitor resistance. Nature Rev Cancer 2015;15:261–275.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir